Key facts
- It has raised $15.4M; the latest was Early Stage VC ($14.1M) in Nov 2025.
- Notable investors include Cowin Capital, Suzhou Angel Fund of Funds, Soochow Venture Capital, WinDigital Capital Management, BrightGene Bio-Medical Technology Company — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Oralead Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Oralead Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oralead Pharma
Developer of oral drug delivery technology platform for drug research. The company focuses on the research of macromolecular oral delivery technology, providing patients with high clinical value and patient compliance.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2022
- Website
- oralead.com/
- Ownership
- Privately Held (backing)
Oralead Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oralead Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oralead Pharma in its N-PORT filings yet. We sweep new filings monthly.